Jordan, K <br/><br/>
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  08 2016 
 - 127-34 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2016.05.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Ascites--drug therapy<br/>Bevacizumab--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Gastrointestinal Neoplasms--complications<br/>Humans<br/>Injections, Intraperitoneal<br/>Male<br/>Middle Aged<br/>Survival Analysis<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors